№ files_lp_3_process_9_07408
File format: docx Character count: 187896 File size: 282 KB
This document outlines a request for project proposals for developing mRNA vaccines to address pandemic influenza and emerging infectious diseases, focusing on long-term partnerships for rapid vaccine development and response capability.
Year: 2024
Region / City: United States
Subject: Pandemic influenza, vaccine development, emerging infectious diseases
Document Type: Request for Proposals (RFP)
Organization: Biomedical Advanced Research and Development Authority (BARDA)
Author: BARDA
Target Audience: Product developers, medical and pharmaceutical industry
Period of Validity: 2024–2025
Date of Approval: August 30, 2024
Date of Amendments: October 28, 2024, November 19, 2024
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Request for Project Proposals (RPP) Solicitation Number: RRPV 24-03-SmMol “COVID-19 Small Molecule Therapeutics for PrEP”
Year: 2024
Region / city: United States
Subject: COVID-19 therapeutics development
Document type: Request for Proposals (RFP)
Organ / institution: Biomedical Advanced Research and Development Authority (BARDA)
Author: Biomedical Advanced Research and Development Authority (BARDA)
Target audience: Product developers, biomedical organizations
Period of validity: 2024–2027
Approval date: 05 August 2024
Amendment date: 20 August 2024
Ashim Subedee: Director of Catalyst Office at BARDA
Year: 2026
Region / City: United States, Washington D.C.
Theme: Health Security Innovation, Biomedical Research
Document Type: Biography
Organization: Biomedical Research & Development Authority (BARDA)
Author: Ashim Subedee
Target Audience: Researchers, Health Innovators, Policy Makers
Date of Approval: N/A
Date of Changes: N/A
Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Request for Project Proposals (RPP) Solicitation Number: RRPV 24-03-SmMol “COVID-19 Small Molecule Therapeutics for PrEP”
Year: 2024
Region / city: United States
Subject: COVID-19 therapeutics development
Document type: Request for Proposals (RFP)
Organ / institution: Biomedical Advanced Research and Development Authority (BARDA)
Author: Biomedical Advanced Research and Development Authority (BARDA)
Target audience: Product developers, biomedical organizations
Period of validity: 2024–2027
Approval date: 05 August 2024
Amendment date: 20 August 2024
UPLC chromatographic profiles and mass analysis of phytochemical compounds in crude and purified RPP
Year: 2023
Region / Location: Not specified
Subject: Phytochemical analysis
Document Type: Supplementary material
Institution: Not specified
Authors: Not specified
Target Audience: Researchers in phytochemistry
Methodology: UPLC and mass spectrometry
Compounds analyzed: HHDP-glucose, Shikimic acid, Citric acid, Salicylic acid, Quinic acid, Ferullic acid hexoside, Gallic acid, Pyrogallic acid, Galloylshikimic acid, Protocatechuic acid, 4-Hydroxybenzoic acid, Quercetin hexuronide, Coumaryl hexoside, Kaempferol derivatives, Procyanidins, Ellagic acid derivatives, Catechin, Apigenin glucoside, Epicatechin-O-gallate, Vanillic acid glycoside
Data: Retention time, mass-to-charge ratio, MS2 fragments, concentration, references
Analysis focus: Comparison between crude and purified RPP extracts
Request for Interview Regarding CSforAll RPP Project Evaluation for 2017-2019 Grants
Year: 2017-2019
Region / City: N/A
Subject: CSforAll RPP Grant Evaluation
Document Type: Email
Organization: RTI International
Author: N/A
Target Audience: NSF CSforAll RPP grantees
Period of Validity: N/A
Approval Date: N/A
Modification Date: N/A
OMB Clearance Number: 3145-0215
Context: Invitation for an interview about the CSforAll RPP funded grants in 2017-2019 for evaluation of long-term outputs and outcomes.
Evaluation of NSF CSforAll RPP Grants Funded in 2017-2019
Year: 2017-2019
Organization: National Science Foundation (NSF)
Project: CSforAll Research-Practice Partnerships (RPPs)
Evaluator: RTI International
Consultant: SageFox Consulting
Start Date: July 2023
Duration: 2-4 years
Purpose: Assessment of long-term outcomes and impacts of CSforAll RPPs
Target Audience: NSF, Congress, CSforAll RPP grantees
Data Sources: Grant reports, interviews, surveys
Research Focus: Professional development for CS teachers, instructional materials for K-8, multi-grade CS pathways, sustained partnerships
Topics: RRPV-24-08-mRNALongTerm BARDA RPP